An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use

European Archives of Psychiatry and Clinical Neuroscience

Volumn 269, Issue 1, 2019, Pages 73-86

  Budney, Alan J ^a   Sofis, Michael J ^a   Borodovsky, Jacob T ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabis; Cannabis use disorder; Legalization; Marijuana; Policy; Prevalence; Treatment

Indexed keywords

CANNABIS; MEDICAL CANNABIS; RECREATIONAL DRUG;

ANXIETY DISORDER; CANNABIS ADDICTION; CANNABIS USE; DISEASE SEVERITY; DSM-5; HEALTH CARE POLICY; HELP SEEKING BEHAVIOR; HUMAN; ICD-10; ICD-11; MOOD DISORDER; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; LEGISLATION AND JURISPRUDENCE; PATHOPHYSIOLOGY;

HEALTH POLICY; HUMANS; MARIJUANA ABUSE; MARIJUANA USE;

EID: 85059505564     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-018-0976-1     Document Type: Review

References (139)

1. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. World Health Organization, Geneva
2. Zehra A, Burns J, Kure Liu C, Manza P, Wiers C, Volkow N, Wang G (2018) Cannabis addiction and the brain: a review. J Neuroimmune Pharmacol 1–15. 10.1007/s11481-018-9782-9
3. APA (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Publishing, Arlington
4. Budney AJ, Roffman R, Stephens RS, Walker D (2007) Marijuana dependence and its treatment. Addict Sci Clin Pract 4(1):4–16
5. Bloomfield MAP, Ashok AH, Volkow ND, Howes OD (2016) The effects of ∆9-tetrahydrocannabinol on the dopamine system. Nature 539:369. 10.1038/nature20153
6. Vandrey R, Haney M (2009) Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 23(7):543–553
7. ElSohly (2005) Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 78:539–548
8. Budney AJ, Lile JA (2009) Moving beyond the cannabis controversy into the world of the cannabinoids. Int Rev Psychiatry 21(2):91–95. 10.1080/09540260902782729
9. Budney AJ, Borodovsky JT (2017) The potential impact of cannabis legalization on the development of cannabis use disorders. Prev Med. 10.1016/j.ypmed.2017.06.034
10. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z (2008) Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat 35(4):362–368. 10.1016/j.jsat.2008.01.002 pii]
11. Hasin DS, Kerridge BT, Saha TD, Huang B, Pickering R, Smith SM, Jung J, Zhang H, Grant BF (2016) Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: findings from the national epidemiologic survey on alcohol and related conditions–III. Am J Psychiatry 173(6):588–599. 10.1176/appi.ajp.2015.15070907
12. WHO (2016) The Health and social effects of nonmedical cannabis use. Geneva, Switzerland
13. UNODC (2018) World drug report: pre-briefing to the member states. United Nations Office on Drugs and Crime, Vienna
14. SAMHSA (2017) Results from the 2016 national survey on drug use and health: detailed tables. Prevalence estimates, standard Errors, P Values, and sample sizes. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, Rockville
15. Mauro PM, Carliner H, Brown QL, Hasin DS, Shmulewitz D, Rahim-Juwel R, Sarvet AL, Wall MM, Martins SS (2018) Age differences in daily and nondaily cannabis use in the United States, 2002–2014. J Stud Alcohol Drugs 79(3):423–431. 10.15288/jsad.2018.79.423
16. Degenhardt L, Ferrari AJ, Calabria B, Hall W, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T (2013) The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 Study. Plos ONE 8(10):e76635. 10.1371/journal.pone.0076635
17. Pabst A, Kraus L, Gomes de Matos E, Piontek D (2013) Substance use and substance use disorders in Germany in 2012. SUCHT 59:321–331
18. Teesson M, Slade T, Swift W, Mills K, Memedovic S, Mewton L, Grove R, Newton N, Hall W (2012) Prevalence, correlates and comorbidity of DSM-IV cannabis use and cannabis use disorders in Australia. Aust N Z J Psychiatry 46(12):1182–1192
19. Grucza RA, Agrawal A, Bierut LJ (2016) NESARC Findings on increased prevalence of marijuana use disorders—reply consistent with other sources of information. JAMA Psychiatry 73(5):532–533. 10.1001/jamapsychiatry.2016.0244
20. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF (2015) Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 72(12):1235–1242. 10.1001/jamapsychiatry.2015.1858
21. Grucza RA, Agrawal A, Krauss MJ, Cavazos-Rehg PA, Bierut LJ (2016) Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry 73(3):300–301. 10.1001/jamapsychiatry.2015.3111
22. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, Jung J, Zhang H, Fan A, Hasin DS (2017) Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the national epidemiologic survey on alcohol and related conditions. JAMA Psychiatry 74(9):911–923. 10.1001/jamapsychiatry.2017.2161
23. Chou SP, Goldstein RB, Smith SM, Huang B, Ruan WJ, Zhang H, Jung J, Saha TD, Pickering RP, Grant BF (2016) The epidemiology of DSM-5 nicotine use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. J Clin Psychiatry 77(10):1404–1412. 10.4088/JCP.15m10114
24. Budney AJ (2006) Are specific dependence criteria necessary for different substances: how can research on cannabis inform this issue? Addiction 101:125–133
25. Shmulewitz D, Greene ER, Hasin D (2015) Commonalities and differences across substance use disorders: phenomenological and epidemiological aspects. Alcohol Clin Exp Res 39(10):1878–1900. 10.1111/acer.12838
26. Budney AJ, Hughes JR (2006) The cannabis withdrawal syndrome. Curr Opin Psychiatry 19(3):233–238
27. Peer K, Rennert L, Lynch KG, Farrer L, Gelernter J, Kranzler HR (2013) Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample. Drug Alcohol Depend 127(0):215–219
28. Kerridge BT, Pickering R, Chou P, Saha TD, Hasin DS (2018) DSM-5 cannabis use disorder in the national epidemiologic survey on alcohol and related conditions-III: gender-specific profiles. Addict Behav 76:52–60
29. Kimbrel N, Meyer E, DeBeer B, Gulliver S, Morissette S (2018) The impact of cannabis use disorder on suicidal and nonsuicidal self-injury in Iraq/Afghanistan-era veterans with and without mental health disorders. Suicide Life Threat Behav 48(2):140–148
30. Campbell CI, Bahorik AL, Kline-Simon AH, Satre DD (2017) The role of marijuana use disorder in predicting emergency department and inpatient encounters: a retrospective cohort study. Drug Alcohol Depend 178:170–175
31. Crean RD, Crane NA, Mason BJ (2011) An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 5(1):1–8. 10.1097/ADM.0b013e31820c23fa
32. Kowal MA, van Steenbergen H, Colzato LS, Hazekamp A, van der Wee NJA, Manai M, Durieux J, Hommel B (2015) Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users. Eur Neuropsychopharmacol 25(11):1943–1953
33. Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, Bloomfield MA, Curran HV, Baler R (2016) Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 73(3):292–297. 10.1001/jamapsychiatry.2015.3278
34. Solowij N, Battisti R (2008) The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 1(1):81–98
35. Lorenzetti V, Alonso-Lana S, Youssef GJ, Verdejo-Garcia A, Suo C, Cousijn J, Takagi M, Yücel M, Solowij N (2016) Adolescent cannabis use: what is the evidence for functional brain alteration? Curr Pharm Des 22(42):6353–6365. 10.2174/1381612822666160805155922
36. Jernigan TL, Brown SA, Coordinators AC (2018) Introduction. Dev Cogn Neurosci 32: The Adolescent Brain Cognitive Development (ABCD) Consortium: Rationale, aims, and assessment strategy:1–3
37. Farmer RFK, Seeley DB, Gau JR, Duncan JM, Walker SC, Lewinsohn DD PM (2016) Association of comorbid psychopathology with the duration of cannabis use disorders. Psychol Addict Behav 30(1):82–92
38. Agrawal A, Budney AJ, Lynskey MT (2012) The co-occurring use and misuse of cannabis and tobacco: a review. Addiction. 10.1111/j.1360-0443.2012.03837.x
39. Lee DC, Budney AJ, Brunette MF, Hughes JR, Etter JF, Stanger C (2015) Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use. Drug Alcohol Depend 155:134–140. 10.1016/j.drugalcdep.2015.08.001
40. Florez-Salamanca L, Secades-Villa R, Hasin DS, Cottler L, Wang S, Grant BF, Blanco C (2013) Probability and predictors of transition from abuse to dependence on alcohol, cannabis, and cocaine: results from the national epidemiologic survey on alcohol and related conditions. Am J Drug Alcohol Abuse 39(3):168–179
41. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J (2013) Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry 54(6):589–598
42. Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, Okuda M, Wang S, Grant BF, Blanco C (2011) Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the national epidemiologic survey on alcohol and related conditions (NESARC). Drug Alcohol Depend 115(1–2):120–130. 10.1016/j.drugalcdep.2010.11.004
43. Martins SS, Gorelick DA (2011) Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend 119(1–2):28–36
44. Cheung JT, Mann RE, Ialomiteanu A, Stoduto G, Chan V, Ala-Leppilampi K, Rehm J (2010) Anxiety and mood disorders and cannabis use. Am J Drug Alcohol Abuse 36(2):118–122. 10.3109/00952991003713784
45. Zvolensky MJ, Cougle JR, Johnson KA, Bonn-Miller MO, Bernstein A (2010) Marijuana use and panic psychopathology among a representative sample of adults. Exp Clin Psychopharmacol 18(2):129–134. 10.1037/a0019022
46. Degenhardt L, Hall W, Lynskey M (2001) The relationship between cannabis use, depression and anxiety among Australian adults: findings from the national survey of mental health and well-being. Soc Psychiatry Psychiatr Epidemiol 36(5):219–227. doi:10.1007/s001270170052
47. Stinson FS, Ruan WJ, Pickering R, Grant BF (2006) Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 36(10):1447–1460. 10.1017/S0033291706008361
48. Borodovsky JT, Budney AJ (2018) Cannabis regulatory science: risk–benefit considerations for mental disorders. Int Rev Psychiatry:1–20. 10.1080/09540261.2018.1454406
49. Goldenberg M, Reid MW, IsHak WW, Danovitch I (2017) The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: a systematic review and meta-analysis. Drug Alcohol Depend 174:80–90
50. Montanari L, Guarita B, Mounteney J, Zipfel N, Simon R (2017) Cannabis use among people entering drug treatment in Europe: a growing phenomenon? Eur Addict Res 23(3):113–121
51. SAMHSA (2017) Treatment Episode Data Set (TEDS): 2005–2015. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-91, HHS Publication No. (SMA) 17-5037. Substance Abuse and Mental Health Services Administration, Rockville
52. SAMSHA (2004) Treatment Episode Data Set 2002 SPSS Data
53. SAMHSA (2017) Treatment Episode Data Set 2015 SPSS Data
54. Johnston LD, Miech RA, O’Malley PM, Bachman JG, Schulenberg JE, Patrick ME (2017) Monitoring the Future national survey results on drug use: 1975–2017: Overview, key findings on adolescent drug use. Institute for Social Research, The University of Michigan, Ann Arbor
55. Wu LT, Zhu H, Mannelli P, Swartz MS (2017) Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States. Drug Alcohol Depend 177:153–162
56. Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, Hasin DS (2016) Epidemiology of DSM-5 drug use disorder: results from the national epidemiologic survey on alcohol and related conditions-III. JAMA Psychiatry 73(1):39–47. 10.1001/jamapsychiatry.2015.2132
57. Blanco C, Iza M, Rodríguez-Fernández JM, Baca-García E, Wang S, Olfson M (2015) Probability and predictors of treatment-seeking for substance use disorders in the U.S. Drug Alcohol Depend 149:136–144
58. Gates P, Copeland J, Swift W, Martin G (2012) Barriers and facilitators to cannabis treatment. Drug Alcohol Rev 31(3):311–319. 10.1111/j.1465-3362.2011.00313.x
59. van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M (2013) Facilitators and barriers in treatment seeking for cannabis dependence. Drug Alcohol Depend 133(2):776–780. 10.1016/j.drugalcdep.2013.08.011
60. Budney AJ, Radonovich KJ, Higgins ST, Wong CJ (1998) Adults seeking treatment for marijuana dependence: a comparison to cocaine-dependent treatment seekers. Exp Clin Psychopharmacol 6(4):419–426
61. Stephens RS, Babor TF, Kadden R, Miller M (2002) The marijuana treatment project: Rationale, design, and participant characteristics. Addiction 97(S1):109–124
62. Knapp AA, Babbin SF, Budney AJ, Walker DD, Stephens RS, Scherer EA, Stanger C (2018) Psychometric assessment of the marijuana adolescent problem inventory. Addict Behav 79(4):113–119
63. WHO ASSIST Working Group (2002) The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction 97(9):1183–1194
64. Legleye S, Karila L, Beck F, Reynaud M (2007) Validation of the CAST, a general population cannabis abuse screening test. J Subst Use 12(4):233–242
65. Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, Sellman JD (2010) An improved brief measure of cannabis misuse: the cannabis use disorders identification test-revised (CUDIT-R). Drug Alcohol Depend 110(1–2):137–143. 10.1016/j.drugalcdep.2010.02.017
66. Martin G, Copeland J, Gilmour S, Gates P, Swift W (2006) The adolescent cannabis problems questionnaire (CPQ-A): psychometric properties. Addict Behav 31(12):2238–2248. 10.1016/j.addbeh.2006.03.001
67. Bashford J, Flett R, J. C (2010) The cannabis use problems identification test (CUPIT): development, reliability, concurrent and predictive validity among adolescents and adults. Addiction 105(4):615–625
68. White HR, Labouvie EW, Papadaratsakis V (2005) Changes in substance use during the transition to adulthood: a comparison of college students and their noncollege age peers. J Drug Issues 35(2):281–306
69. Fernandez-Artamendi S, Fernández-Hermida J, Muñiz-Fernández J, Secades-Villa R, García-Fernández G (2012) Screening of cannabis-related problems among youth: the CPQ-A-S and CAST questionnaires. J Subst Abuse Treat Prev Policy 7(1):13. 10.1186/1747-597x-7-13
70. Halladay J, Petker T, Fein A, Munn C, MacKillop JJSR (2018) Brief interventions for cannabis use in emerging adults: protocol for a systematic review, meta-analysis, and evidence map. Syst Rev 7(1):106. 10.1186/s13643-018-0772-z
71. Hughes JR, Naud S, Budney AJ, Fingar JR, Callas PW (2016) Attempts to stop or reduce daily cannabis use: an intensive natural history study. Psychol Addict Behav 30(3):389–397. 10.1037/adb0000155
72. Hughes JR, Peters EN, Callas PW, Budney AJ, Livingston A (2008) Attempts to stop or reduce marijuana use in non-treatment seekers. Drug Alcohol Depend 97:180–184
73. Hughes JR, Fingar JR, Budney AJ, Naud S, Helzer JE, Callas PW (2014) Marijuana use and intoxication among daily users: an intensive longitudinal study. Addict Behav 39(10):1464–1470. 10.1016/j.addbeh.2014.05.024
74. Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lynskey M, Callaghan B, Rana U, McLaren J (2010) Systematic review of prospective studies investigating “remission” from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav 35(8):741–749
75. von Sydow K, Lieb R, Pfister H, Hofler M, Sonntag H, Wittchen H (2001) The natural course of cannabis use, abuse and dependence over four years: a longitudinal community study of adolescents and young adults. Drug Alcohol Depend 64:347–361
76. Budney AJ, Vandrey R, Fearer SA (2011) Cannabis (marijuana). In: Ruiz P, Strain E (eds) Lowenson & Ruiz’s substance abuse: a comprehensive textbook, 5th edn. Lippincott Williams & Wilkins, Baltimore, pp 214–237
77. Budney AJ, Vandrey RG, Stanger C (2010) Pharmacological and psychosocial interventions for cannabis use disorders. Rev Bras Psiquiatr 32(Suppl 1):S46–S55
78. Cooper K, Chatters R, Kaltenthaler E, Wong R (2015) Psychological and psychosocial interventions for cannabis cessation in adults: a systematic review short report. Health Technol Assess 19(56):1–130. 10.3310/hta19560
79. Danovitch I, Gorelick DA (2012) State of the art treatments for cannabis dependence. Psychiatric Clin of N Am 35(2):309–326. 10.1016/j.psc.2012.03.003
80. Davis ML, Powers MB, Handelsman P, Medina JL, Zvolensky M, Smits JA (2015) Behavioral therapies for treatment-seeking cannabis users: a meta-analysis of randomized controlled trials. Eval Health Prof 38(1):94–114. 10.1177/0163278714529970
81. Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L (2016) Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev (5):CD005336. 10.1002/14651858.CD005336.pub4
82. Sherman BJ, McRae-Clark AL (2016) Treatment of cannabis use disorder: current ccience and future outlook. Pharmacotherapy 36(5):511–535. 10.1002/phar.1747
83. Budney AJ, Stanger C, Knapp AA, Walker DD (2018) Status update on the treatment of cannabis use disorder. In: Winters KC, Sabet KA (eds) Contemporary health issues on marijuana. Oxford University Press, New York, pp 236–255
84. Parmar A, Sarkar S (2017) Brief interventions for cannabis use disorders. Rev Addict Dis Treat 16(2):80–93
85. Budney AJ, Borodovsky JT, Marsch LA, Knapp AA (In press) Technological innovations in addiction treatment. In: Danovitch I, Mooney L (eds) The Assessment and Treatment of Addiction: Best Practices and New Frontiers. Elsevier
86. Marsch LA, Carroll KM, Kiluk BD (2014) Technology-based interventions for the treatment and recovery management of substance use disorders: a JSAT special issue. J Subst Abuse Treat 46(1):1–4. 10.1016/j.jsat.2013.08.010
87. Schaub MP, Wenger A, Berg O, Beck T, Stark L, Buehler E, Haug S (2015) A web-based self-help intervention with and without chat counseling to reduce cannabis use in problematic cannabis users: three-arm randomized controlled trial. J Med Internet Res 17(10):e232. 10.2196/jmir.4860
88. Hogue A, Henderson CE, Ozechowski TJ, Robbins MS (2014) Evidence base on outpatient behavioral treatments for adolescent substance use: updates and recommendations 2007–2013. J Clin Child Adolesc Psychol 43(5):695–720. 10.1080/15374416.2014.915550
89. Simpson AK, Magid V (2016) Cannabis use disorder in adolescence. Child Adolesc Psychiatr Clin N Am 25(3):431–443. 10.1016/j.chc.2016.03.003
90. Stanger C, Lansing AH, Budney AJ (2016) Advances in research on contingency management for adolescent substance use. Child Adolesc Psychiatr Clin N Am 25(4):645–659. 10.1016/j.chc.2016.05.002
91. Tanner-Smith EE, Wilson SJ, Lipsey MW (2013) The comparative effectiveness of outpatient treatment for adolescent substance abuse: a meta-analysis. J Subst Abuse Treat 44:145–158
92. Waldron HB, Turner CW (2008) Evidence-based psychosocial treatments for adolescent substance abuse. J Clin Child Adolesc Psychol 37(1):238–261. 10.1080/15374410701820133
93. Winters KC, Tanner-Smith EE, Bresani E, Meyers K (2014) Current advances in the treatment of adolescent drug use. Adolesc Health Med Ther 5:199–210. 10.2147/AHMT.S48053
94. Winters KC, Botzet AM, Fahnhorst T (2011) Advances in adolescent substance abuse treatment. Curr Psychiatry Rep 13(5):416–421. 10.1007/s11920-011-0214-2
95. Hogue A, Henderson CE, Becker SJ, Knight DK (2018) Evidence base on outpatient behavioral treatments for adolescent substance use, 2014–2017: outcomes, treatment delivery, and promising horizons. J Clin Child Adolesc Psychol 47(4):499–526. 10.1080/15374416.2018.1466307
96. Liddle HA, Rowe CL, Dakof GA, Ungaro RA, Henderson CE (2004) Early intervention for adolescent substance abuse: pretreatment to posttreatment outcomes of a randomized clinical trial comparing multidimensional family therapy and peer group treatment. J Psychoactive Drugs 36(1):49–63
97. Marsch LA, Borodovsky JT (2016) Technology-based interventions for preventing and treating substance use among youth. Child Adolesc Psychiatric Clin N Am 25(4):755–768. 10.1016/j.chc.2016.06.005
98. Gorelick DA (2016) Pharmacological treatment of cannabis-related disorders: a narrative review. Curr Pharm Des 22(42):6409–6419. 10.2174/1381612822666160822150822
99. Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR (2017) A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 177:249–257. 10.1016/j.drugalcdep.2017.04.020
100. Copeland J, Pokorski I (2016) Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. Subst Abuse Rehabil 7:41–53. 10.2147/SAR.S89857
101. Mason BJ, Mustafa A, Filbey F, Brown ES (2016) Novel pharmacotherapeutic interventions for cannabis use disorder. Curr Addict Rep 3(2):214–220
102. Denis C, Lavie E, Fatseas M, Auriacombe M (2006) Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 3. 10.1002/14651858.CD005336.pub2
103. Hall W, Lynskey M (2016) Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. Lancet Psychiatry 3(9):900–906
104. Wen H, Hockenberry JM, Druss BG (2018) The effect of medical marijuana laws on marijuana-related attitude and perception among US adolescents and young adults. Prev Sci. 10.1007/s11121-018-0903-8
105. Hasin DS (2017) US epidemiology of cannabis use and associated problems. Neuropsychopharmacology 43:195. 10.1038/npp.2017.198
106. Carlini BH, Garrett SB, Harwick RM (2017) Beyond joints and brownies: Marijuana concentrates in the legal landscape of WA State. Int J Drug Policy 42:26–29. 10.1016/j.drugpo.2017.01.004
107. Borodovsky JT, Crosier BS, Lee DC, Sargent JD, Budney AJ (2016) Smoking, vaping, eating: is legalization impacting the way people use cannabis? Int J Drug Policy 36:141–147. 10.1016/j.drugpo.2016.02.022
108. Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ (2017) Pharmacokinetic profile of oral cannabis in humans: blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol 41 1–17. 10.1093/jat/bkx012
109. Loflin M, Earleywine M (2014) A new method of cannabis ingestion: the dangers of dabs? Addict Behav 39(10):1430–1433. 10.1016/j.addbeh.2014.05.013
110. Volkow N, Baler R, Compton W, Weiss S (2014) Adverse health effects of marijuana use. N Engl J Med 370(23):2219–2227
111. Paul CL, Mee KJ, Judd TM, Walsh RA, Tang A, Penman A, Girgis A (2010) Anywhere, anytime: retail access to tobacco in New South Wales and its potential impact on consumption and quitting. Soc Sci Med 71(4):799–806. 10.1016/j.socscimed.2010.05.011
112. Casswell S, Morojele N, Williams PP, Chaiyasong S, Gordon R, Gray-Philip G, Viet Cuong P, MacKintosh AM, Halliday S, Railton R, Randerson S, Parry CDH (2018) The alcohol environment protocol: a new tool for alcohol policy. Drug Alcohol Rev. 10.1111/dar.12654
113. Bickel WK, Johnson MW, Koffarnus MN, MacKillop J, Murphy JG (2014) The behavioral economics of substance use disorders: reinforcement pathologies and their repair. Annu Rev Clin Psychol 10:641–677. 10.1146/annurev-clinpsy-032813-153724
114. Borodovsky JT, Lee DC, Crosier BS, Gabrielli JL, Sargent JD, Budney AJ (2017) U.S. cannabis legalization and use of vaping and edible products among youth. Drug Alcohol Depend 177:299–306. 10.1016/j.drugalcdep.2017.02.017
115. Lee DC, Crosier BS, Borodovsky JT, Sargent JD, Budney AJ (2016) Online survey characterizing vaporizer use among cannabis users. Drug Alcohol Depend 159:227–233. 10.1016/j.drugalcdep.2015.12.020
116. Borodovsky JT, Budney AJ (2017) Legal cannabis laws, home cultivation, and use of edible cannabis products: a growing relationship? Int J Drug Policy 50:102–110. 10.1016/j.drugpo.2017.09.014
117. Caulkins JP, Kilmer B, MacCoun RJ, Pacula RL, Reuter PH (2012) Design considerations for legalizing cannabis: lessons inspired by analysis of California’s proposition 19. Addiction 107(5):865–871
118. Pacula RL, Kilmer B, Wagenaar AC, Chaloupka FJ, Caulkins JP (2014) Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health 104(6):1021–1028. 10.2105/AJPH.2013.301766
119. Chaloupka FJ, Straif K, Leon ME (2010) Effectiveness of tax and price policies in tobacco control. Tobacco Control. 10.1136/tc.2010.039982
120. Chaloupka FJ, Cummings KM, Morley CP, Horan JK (2002) Tax, price and cigarette smoking: Evidence from the tobacco documents and implications for tobacco company marketing strategies. Tob Control 11(suppl 1):I62–I72. 10.1136/tc.11.suppl_1.i62
121. Farrell S, Manning WG, Finch MD (2003) Alcohol dependence and the price of alcoholic beverages. J Health Econ 22(1):117–147
122. DiFranza JR, Wellman RJ, Sargent JD, Weitzman M, Hipple BJ, Winickoff JP, Tobacco Consortium CfCHRotAAoP (2006) Tobacco promotion and the initiation of tobacco use: assessing the evidence for causality. Pediatrics 117(6):e1237–e1248. 10.1542/peds.2005-1817
123. Pechmann C, Knight SJ (2002) An experimental investigation of the joint effects of advertising and peers on adolescents’ beliefs and intentions about cigarette consumption. J Consum Res 29(1):5–19. 10.1086/339918
124. Landman A, Cortese DK, Glantz S (2008) Tobacco industry sociological programs to influence public beliefs about smoking. Soc Sci Med 66(4):970–981. 10.1016/j.socscimed.2007.11.007
125. Evans N, Farkas A, Gilpin E, Berry C, Pierce JP (1995) Influence of tobacco marketing and exposure to smokers on adolescent susceptibility to smoking. J Natl Cancer Inst 87(20):1538–1545
126. Biener L, Siegel M (2000) Tobacco marketing and adolescent smoking: more support for a causal inference. Am J Public Health 90(3):407–411
127. DeWit DJ, Adlaf EM, Offord DR, Ogborne AC (2000) Age at first alcohol use: a risk factor for the development of alcohol disorders. Am J Psychiatry 157(5):745–750. 10.1176/appi.ajp.157.5.745
128. Chen C-Y, O’Brien MS, Anthony JC (2005) Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. Drug Alcohol Depend 79:11–22
129. Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen H-U (2008) The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 103(3):439–449. 10.1111/j.1360-0443.2007.02064.x
130. Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC (2008) Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. Addiction 103(8):1361–1370. 10.1111/j.1360-0443.2008.02246.x
131. Agrawal A, Grant JD, Waldron M, Duncan AE, Scherrer JF, Lynskey MT, Madden PA, Bucholz KK, Heath AC (2006) Risk for initiation of substance use as a function of age of onset of cigarette, alcohol and cannabis use: findings in a midwestern female twin cohort. Prev Med 43(2):125–128. 10.1016/j.ypmed.2006.03.022
132. D’Amico EJ, Miles JNV, Tucker JS (2015) Gateway to curiosity: medical marijuana ads and intention and use during middle school. Psychol Addict Behav 29(3):613–619. 10.1037/adb0000094
133. Roditis ML, Delucchi K, Chang A, Halpern-Felsher B (2016) Perceptions of social norms and exposure to pro-marijuana messages are associated with adolescent marijuana use. Prev Med 93:171–176. 10.1016/j.ypmed.2016.10.013
134. Schuermeyer J, Salomonsen-Sautel S, Price RK, Balan S, Thurstone C, Min SJ, Sakai JT (2014) Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003-11. Drug Alcohol Depend 140:145–155. 10.1016/j.drugalcdep.2014.04.016
135. D’Amico EJ, Rodriguez A, Tucker JS, Pedersen ER, Shih RA (2018) Planting the seed for marijuana use: changes in exposure to medical marijuana advertising and subsequent adolescent marijuana use, cognitions, and consequences over seven years. Drug Alcohol Depend 188:385–391. 10.1016/drugalcdep.2018.03.031
136. Barry RA, Glantz S (2016) A public health framework for legalized retail marijuana based on the US experience: avoiding a new tobacco industry. PLoS Med 13(9):e1002131. 10.1371/journal.pmed.1002131
137. Caulkins JP, Kilmer B, Kleiman MAR (2016) Marijuana legalization: What everyone needs to know, 2 edn. Oxford University Press, New York. 10.7249/CB525-1
138. Kilmer B (2014) Policy designs for cannabis legalization: starting with the eight Ps. Am J Drug Alcohol Abuse 40(4):259–261. 10.3109/00952990.2014.894047
139. Richter KP, Levy S (2014) Big marijuana–lessons from big tobacco. N Engl J Med 371(5):399–401. 10.1056/NEJMp1406074